Table 2.

Summary of the epileptic patients enrolled in the study: responders (R) and non-responders (NR) under therapy with AEDs.

	Patients	Gender	Age	Age at onset	Seiz/trimester	AEDs	Type of seiz	MRI
Responder	1 R	F	52	12	4	CBZ + TOP	FOC	N
	2 R	M	27	18	2	LMT + PB	GEN	N
	3 R	F	57	16	0	FELB + CBZ	FOC	N
	4 R	M	74	9	3	CBZ + LEV	FOC	N
	5 R	F	27	19	1	LEV + PB	GEN	N
	6 R	M	45	15	0	LMT + TOP + CBZ	FOC	SWMG
	7 R	F	76	11	1	CBZ + LMT	FOC	SWMG
	8 R	F	44	8	3	LMT + LEV + PB	GEN	SWMG
	9 R	F	43	16	1	OXC + TOP	FOC	N
	10 R	M	40	19	4	LMT + TOP	FOC	N
	11 R	F	44	24	2	CBZ + LEV	FOC	N
	12 R	M	80	9	0	LMT + LEV + PB	GEN	N
	13 R	M	67	21	1	OXC + LEV + CBZ	FOC	SWMG
	14 R	F	41	26	0	FELB + CBZ	FOC	N
	15 R	F	41	15	4	LMT + CBZ	FOC	N
	16 R	F	27	21	1	LMT + TOP	GEN	N
	17 R	F	37	12	5	OXC + LEV	FOC	SWMG
	18 R	F	33	22	3	CBZ + LMT	GEN	N
Non-responder	1 NR	F	41	14	34	CBZ + LEV	FOC	N
	2 NR	F	54	17	40	LMT + TOP	FOC	SWMG
	3 NR	F	42	23	38	CBZ + TOP + VNS	FOC	1NR
	4 NR	F	55	8	22	PRI + LEV + VNS	GEN	N
	5 NR	M	44	12	30	CBZ + FELB	FOC	N
	6 NR	M	44	20	52	OXC + LEV	FOC	SWMG
	7 NR	F	63	14	18	PB + CBZ	GEN	N
	8 NR	F	70	16	28	CBZ + LEV	FOC	N
	9 NR	F	71	18	12	LMT + FELB	FOC	N
	10 NR	M	46	9	38	CBZ + TOP	FOC	SWMG
	11 NR	F	48	11	32	PB + LEV + LMT	FOC	N
	12 NR	M	58	26	14	OXC + LEV	GEN	N
	13 NR	F	60	11	51	LMT + LEV + TOP	FOC	SWMG
	14 NR	M	48	16	22	PB + TOP	GEN	N
	15 NR	M	41	25	18	FELB + CBZ	GEN	N
	16 NR	F	49	8	24	CBZ + LEV	FOC	N
	17 NR	F	53	13	36	LMT + TOP + CBZ	GEN	N

AEDs, antiepileptic drugs; CBZ, carbamazepine; LEV, levetiracetam; LMT, lamotrigine; TOP, topiramate; VNS, vagal nerve stimulation; FELB, felbamate; PB, phenobarbital; OXC, oxcarbazepine; PRI, primidone; type of seizure, focal or generalized; MRI, magnetic resonance imaging; N, normal; SWMG, Small White Matter Gliosis.